Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,905 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07011654RecruitingPhase 1/Phase 2
Study of two drugs for metastatic triple-negative breast cancer
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT07030686Recruiting
Exercise and quality of life in cancer survivors
This study looks at how exercise habits are linked to how cancer survivors feel and their health outcomes. It may help understand if starting to exercise improves well-being.
Duarte, CaliforniaAges 18 years+ - NCT07087860RecruitingPhase 2
Plasma exchange plus targeted therapy for advanced bladder cancer
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
Rochester, MinnesotaAges 18 years+ - NCT07092696RecruitingPhase 2
Immunotherapy and chemoradiation for cervical cancer
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
TianjinAges 18–75 - NCT07149090RecruitingPhase 1/Phase 2
Lenvatinib, Nivolumab, and Chemo in Stomach Cancer with Ascites
This trial tests a combination of two drugs (lenvatinib and nivolumab) plus chemotherapy for people with advanced stomach cancer that has caused fluid buildup in the belly. The goal is to see if this combination can help shrink the cancer and reduce the fluid.
SeoulAges 19 years+ - NCT07190443RecruitingPhase 3
Abemaciclib after local recurrence in HR+ HER2- breast cancer
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
Koto-ku, TokyoAges 18 years+ - NCT07340489RecruitingPhase 2
Serplulimab for locally advanced cervical cancer
This trial tests a new immunotherapy drug, serplulimab, for people with locally advanced cervical cancer. The goal is to see if it can help shrink or control the cancer before standard treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05958121RecruitingPhase 1/Phase 2
IMA402 immune therapy for advanced solid tumors
This trial tests an immune system treatment (IMA402) that is meant to help the body recognize and fight advanced solid tumors. It may be an option if your cancer has come back or did not respond to standard treatments, and if your overall health and tumor measurements meet study requirements.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06315257RecruitingPhase 1
PVX7 vaccine for advanced cervical cancer
This trial tests a new immunotherapy vaccine called PVX7 for women with advanced cervical cancer that is caused by HPV. It aims to see if the vaccine can help prevent the cancer from coming back after standard treatment.
Birmingham, AlabamaAges 18 years+ - NCT07443475RecruitingPhase 2
Electric field therapy for vulvar cancer that has come back
This trial tests whether a targeted electric current can improve treatment for vulvar cancer that has returned after standard therapy. The treatment uses electricity to help chemotherapy drugs enter cancer cells more effectively.
LjubljanaAges 18 years+ - NCT06012734RecruitingPhase 1
LB-100 plus Atezolizumab for metastatic colorectal cancer
This trial tests a new two-drug combination (LB-100 plus atezolizumab) for people with metastatic colorectal cancer that hasn't responded to standard treatment. The goal is to see if the combination can help shrink or slow the cancer.
Amsterdam, North HollandAges 18 years+ - NCT07500298RecruitingPhase 1
New drug plus standard chemo for spread colorectal cancer
This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.
Houston, TexasAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT05366881Recruiting
Blood test study to spot early cancer signal and cancer leftovers
This observational study checks whether a blood test (a “cfDNA” test) can detect early signs of cancer or small amounts of cancer left after treatment. It may help doctors use a simple blood sample to improve cancer detection and follow-up.
Duarte, CaliforniaAges 40 years+ - NCT07059884Recruiting
Exercise program to help people with cancer stay active
This trial tests a distance-based exercise program designed to help people on chemotherapy maintain their physical function and prevent disability. It is for patients with certain cancers who are working full-time and can participate in moderate physical activity.
Dublin, CaliforniaAges 18 years+ - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT05920798RecruitingPhase 1/Phase 2
Vaccine treatment plus pembrolizumab for recurrent ovarian cancer
This Phase 1/2 trial tests a new cancer vaccine therapy combined with pembrolizumab (an immunotherapy) to treat advanced, recurrent ovarian, fallopian tube, or primary peritoneal cancer. It may help your immune system recognize and attack the cancer, especially if your tumor has a specific target called FRα.
Scottsdale, ArizonaAges 18 years+ - NCT03326921RecruitingPhase 1
T cell treatment for leukemia after a bone marrow transplant
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
Seattle, WashingtonAges Up to 80 years - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT07406087Recruiting
Navigation support for young adults after cancer
This study tests a navigation program to help cancer survivors ages 21-45 get the follow-up care they need. It may be a good fit if you were diagnosed with certain cancers as a teen or young adult.
Pasadena, CaliforniaAges 21–45 - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT06028724Recruiting
Looking for cancer mutations using a blood test
This study uses a blood test (liquid biopsy) to find genetic changes in advanced solid tumors. It may help doctors choose the right treatment and monitor how well it works over time.
Aviano, PordononeAges 18 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,905 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.